Tunlametinib is a targeted therapy belonging to the MEK inhibitor class, primarily used to treat specific types of cancer (e.g., melanoma). Its common side effects include skin reactions, gastrointestinal discomfort, fatigue, and others; severe cases may involve hepatic injury or cardiac toxicity, so strict medical supervision and regular monitoring are required.
Common Side Effects
Skin reactions
Rash, pruritus, dry skin, or acneiform dermatitis. Some patients may experience photosensitivity reactions.
Gastrointestinal discomfort
Diarrhea, nausea, vomiting, and abdominal pain, which can usually be relieved by dietary adjustments or medication.
Systemic symptoms
Fatigue, fever, muscle or joint pain.
Edema
Edema of the extremities or face, possibly related to the drug’s effect on vascular permeability.
Serious Side Effects (Seek Immediate Medical Attention)
Hepatic injury
Manifested as jaundice, dark urine, and abdominal pain. Regular liver function monitoring is required.
Cardiac problems
Palpitations, chest pain, dyspnea, which may be associated with myocardial ischemia or left ventricular dysfunction.
Ocular abnormalities
Blurred vision, retinopathy. Ophthalmological evaluation is needed to rule out the risk of retinal vein occlusion.
Severe skin reactions
Such as Stevens-Johnson syndrome (rare but life-threatening).
Precautions for Use
Dosage adjustment under medical guidance
Do not increase or decrease the dosage without authorization. Individualized dosing is especially required for patients with hepatic or renal insufficiency.
Regular monitoring
Including complete blood count (CBC), liver and kidney function tests, electrocardiogram (ECG), and ophthalmological examinations.
Avoid photosensitivity
Take sun protection measures and reduce exposure to ultraviolet (UV) light.
Drug interactions
Concomitant use with CYP3A4 inhibitors or other targeted therapies may potentiate side effects; inform your doctor of your full medication history in advance.
If persistent diarrhea, dyspnea, severe headache, or vision changes occur, discontinue the drug immediately and contact your doctor. Targeted therapy should be prescribed based on the patient’s overall condition, and close follow-up is necessary throughout treatment.
